Indian drugmaker Biocon has announced the signing of an out-licensing agreement with Ajanta Pharma to market its vertically ...

Biocon Biologics, a fully integrated global biosimilars company and subsidiary of India’s Biocon Ltd, announced that it has ...

As per the exchange filing, Biocon Biologics will take responsibility across the product lifecycle, which includes ...

According to PL Capital, Ajanta Pharma's strong franchise will aid in garnering a higher market share for semaglutide ...

Biocon will fully integrate its biosimilars arm, Biocon Biologics into the parent, in a deal valuing the unit at $5.5 billion. The move is aimed at cr.

Ajanta Pharma has signed an in-licensing pact with Biocon to commercialise semaglutide in 26 countries across Africa, the ...

The inspection was conducted by the US FDA between October 6-10, 2025, under current Good Manufacturing Practice (cGMP) ...

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...

Biocon Biologics has gained complete global rights for Hulio, a biosimilar Adalimumab. This move grants Biocon Biologics full ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...

Four pharma stocks to watch today as Lupin signs a peptide API deal, Dr Reddy’s and Aurobindo face FDA observations, and Biocon clears a global launch.

Biocon Ltd will integrate Biocon Biologics Ltd as a wholly owned subsidiary in a deal valuing the unit at $5.5 billion, the company said on Saturday. Biocon will acquire the remaining stake in Biocon ...